Structured evidence table for Olive Leaf Sleep Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Olive Leaf Sleep Meta-Analysis | Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion’s mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Olive Leaf Sleep Meta-Analysis | The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Olive Leaf Sleep Meta-Analysis | It should be noted that the present work consists of a review and not a dosing guideline. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Olive Leaf Sleep Meta-Analysis | 1 1 Brain health is a multidimensional and evolving concept that is difficult to evaluate and quantify []. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Olive Leaf Sleep Meta-Analysis | Research indicates that in developed countries, effective control of risk factors and rational allocation of medical resources have led to a declining trend in CHD prevalence. | 3 | Zeng Zhi (2026) | Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease |
| Olive Leaf Sleep Meta-Analysis | Dyslipidemia is a major risk factor for CHD recurrence and mortality and is primarily manifested as elevated serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, coupled with reduced levels of high-density lipoprotein cholesterol (HDL-C) (,). | 3 | Zeng Zhi (2026) | Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease |
| Olive Leaf Sleep Meta-Analysis | However, most of this evidence focuses on pharmacotherapy (–), and in real-world application, suboptimal patient adherence and insufficient treatment intensity often lead to poor rates of lipid control (–). | 3 | Zeng Zhi (2026) | Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease |
| Olive Leaf Sleep Meta-Analysis | 1 2 3 4 5 6 7 8 9 11 12 14 15 17 18 19 Coronary heart disease (CHD) is a cardiac condition caused by atherosclerosis of the coronary arteries, leading to narrowing, spasm, or even occlusion of the vessel lumen, which in turn triggers myocardial ischemia, hypoxia, or necrosis (). | 3 | Zeng Zhi (2026) | Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease |
Source documents